Relapsed/Refractory Peripheral T Cell Lymphoma

8 clinical trials · Condition

Record	Firm	Date
AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHL (NCT05140382)	AstraZeneca	2021-12-15
Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01) (NCT04703192)	Daiichi Sankyo	2021-06-03

Every clearance here is in the API, with alerts when new ones post.